Bionano Genomics, Inc.
جودة البيانات: 100%
BNGO
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
KWD 1.13
▼
KWD 0.03
(-2.59%)
القيمة السوقية: 12.70 M
السعر
KWD 1.15
القيمة السوقية
12.70 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 12.21% annually over 5 years — strong growth
Negative free cash flow of -16.35 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 19.58%
النمو
Revenue Growth (5Y)
12.21%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)-7.37%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-55.47%
أقل من متوسط القطاع (-53.53%)
ROIC-48.81%
Net Margin-92.59%
Op. Margin-116.95%
الأمان
Debt / Equity
N/A
Current Ratio2.12
Interest CoverageN/A
التقييم
PE (TTM)
-0.48
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.26
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.5 | -1.5 |
| P/B | 0.3 | 1.6 |
| ROE % | -55.5 | -53.5 |
| Net Margin % | -92.6 | -41.5 |
| Rev Growth 5Y % | 12.2 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
2 محللين
Strong Buy
الحالي
KWD 1.13
المستهدف
KWD 5.50
KWD 4.00
KWD 5.50
KWD 7.00
التوقعات
مكرر الربحية المستقبلي
-1.02
ربحية السهم المستقبلية
-KWD 1.11
الإيرادات المقدّرة
43.30 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.11
-KWD 1.11 – -KWD 1.11
|
43.30 M | 1 |
| FY2026 |
-KWD 2.71
-KWD 2.71 – -KWD 2.71
|
32.47 M | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.89
-KWD 0.89 – -KWD 0.89
|
7.64 M | 1 |
| 2026 Q1 |
-KWD 0.95
-KWD 0.95 – -KWD 0.95
|
6.64 M | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 4.14 | -KWD 0.03 | +99.3% |
| Q32025 | -KWD 2.34 | -KWD 1.59 | +32.1% |
| Q22025 | -KWD 2.99 | -KWD 1.97 | +34.0% |
| Q12025 | -KWD 3.02 | -KWD 1.15 | +62.0% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -7.37% | Revenue Growth (3Y) | -11.15% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 12.21% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 28.51 M | Net Income (TTM) | -26.40 M |
| ROE | -55.47% | ROA | -34.04% |
| Gross Margin | N/A | Operating Margin | -116.95% |
| Net Margin | -92.59% | Free Cash Flow (TTM) | -16.35 M |
| ROIC | -48.81% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.12 |
| Interest Coverage | N/A | Asset Turnover | 0.37 |
| Working Capital | 25.82 M | Tangible Book Value | 44.11 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.48 | Forward P/E | N/A |
| P/B Ratio | 0.26 | P/S Ratio | 0.45 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -128.70% | ||
| Market Cap | 12.70 M | Enterprise Value | 9.64 M |
| Per Share | |||
| EPS (Diluted TTM) | -4.85 | Revenue / Share | 2.57 |
| FCF / Share | -1.47 | OCF / Share | -1.47 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 61.92% |
| SBC-Adj. FCF | -22.16 M | Growth Momentum | -19.58 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 28.51 M | 30.78 M | 36.12 M | 27.80 M | 17.98 M |
| Net Income | -26.40 M | -112.02 M | -232.49 M | -132.60 M | -72.44 M |
| EPS (Diluted) | -4.85 | -88.13 | -6.81 | -0.46 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -33.34 M | -103.98 M | -215.25 M | -131.70 M | -77.10 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 11.37 M | 24.80 M | 54.03 M | 49.05 M | 22.49 M |
| SG&A Expenses | 35.15 M | 51.86 M | 93.50 M | 88.60 M | 58.49 M |
| D&A | 9.53 M | 14.02 M | 13.71 M | 9.62 M | 3.35 M |
| Interest Expense | — | — | 5.12 M | 298,000.0 | 927,000.0 |
| Income Tax | 67,000.0 | 33,000.0 | 62,000.0 | 1.88 M | -5.72 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 73.58 M | 76.67 M | 214.40 M | 307.50 M | 377.10 M |
| Total Liabilities | 29.16 M | 41.30 M | 118.25 M | 58.10 M | 39.98 M |
| Shareholders' Equity | 44.42 M | 35.38 M | 96.16 M | 249.40 M | 337.12 M |
| Total Debt | — | — | — | — | 16.33 M |
| Cash & Equivalents | 2.99 M | 9.17 M | 17.95 M | 5.09 M | 24.57 M |
| Current Assets | 45.39 M | 39.49 M | 140.12 M | 157.30 M | 272.41 M |
| Current Liabilities | 22.94 M | 37.34 M | 100.03 M | 35.88 M | 21.84 M |
{"event":"ticker_viewed","properties":{"ticker":"BNGO","listing_kind":"stock","pathname":"/stocks/bngo","exchange":"Nasdaq","country":"US"}}